New branding, same values: xRapid is opening a new chapter

Since its creation in 2015, xRapid expanded very quickly by selling medical diagnostic tests all over the world. The two iPhone apps, xRapid-Lab (used by researchers) and xRapid-Malaria (used in the field), are now sold to retailers, NGOs, hospitals and independent practitioners on four continents. xRapid’s fight against malaria is getting more efficient every day and our impact on global health is now real. After this great medical achievement, xRapid decided to contribute to another global issue: Environment. New branch, new logos, new identity: xRapid is opening a new chapter…



xRapid-Environment: the Group is diversifying its activities



Asbestos is a real threat to the environment and thus public health. Exposure to asbestos fibre causes many forms of cancer (most commonly lung cancer), mesothelioma and asbestosis (lung diseases) and the impairment of respiratory function. Hundreds of millions of people are exposed to asbestos in their workplace and it kills more than 90,000 people every year.

When xRapid’s CTO confirmed that the technology used by our parasite counter apps could also be used to detect asbestos fibres and help prevent an environmental disaster, the decision was made quickly. After seven months of research and testing, xRapid is proud to announce the release of our new product: xRapid-Asbestos, a test kit detecting asbestos fibres in air samples. The technology used is very similar to our previous apps. xRapid-Asbestos will be very useful for the construction industry and is set to launch on the American market at the AIHce Congress in Seattle (June 2017).

“xRapid is going from strength to strength, as we develop new products inspired by the original xRapid-Medical diagnostic for malaria.”

Lord Jim Knight, xRapid’s Chairman



xRapid logos

New structure, new logos, same values

With the release of our new asbestos test kit, xRapid’s board saw the opportunity to launch a new branch: xRapid-Environment. Therefore, three distinct entities have emerged: xRapid-Group, xRapid-Medical and xRapid-Environment.

  • xRapid-Group is based in London and Marseille (where the R&D Centre is, in France).
  • xRapid-Medical, the essence of our activity, is based in London and focuses on medical diagnostic tests (such as malaria).
  • xRapid-Environment, our latest arrival, is based in the US and focuses on environmental diagnostic tests (asbestos for now).

To reflect these changes, we have redesigned our logos (see below).

The rebranding reflects both the evolution of xRapid and our vision for the future. But the value proposition remains the same: we believe in protecting people’s health by disrupting the testing world. We offer better outcomes, not just results. Thus, xRapid’s team is thrilled and more motivated than ever to work on this new environmental project.

Meet xRapid’s team!

A word from the Chairman

“xRapid is going from strength to strength, as we develop new products inspired by the original xRapid-Medical diagnostic for malaria. I am particularly excited by the potential of xRapid-Environment. To reflect these developments we have a new group structure and brand. As Chair of the Group, I will remain focussed on our group strategy and our significant contribution to global health improvement.”

Lord Jim Knight, xRapid’s Chairman.



Brand new premises for xRapid’s R&D Centre

With all these big changes, xRapid felt the necessity to expand the team. 18 people are now working full time in 4 countries and we are expecting other recruitments in the next few months. Currently located on the engineer school campus of the “École des Mines de Saint-Étienne” in the South of France, the R&D Centre will soon be based at On[e]Life, in l’Estaque, Marseille. The building will gather ten other biotech startups. Facilities will be made for medical research and biotechnologies. A 500-m² laboratory is available for the startups. Once the construction site is complete, the R&D team will be moving in, probably in October 2017.


Partnership agreement between xRapid and the French National Reference Centre for Malaria

On Friday, 17th March 2017, xRapid-Group and the French National Reference Centre for Malaria (CNRP and AP-HP) formalised a long run partnership. The two parties were represented by Jean Viry-Babel, xRapid’s CEO, and Marc Thellier, parasitologist and laboratory manager at the CNRP.

The agreement signature took place in the very luxurious Luxembourg Palace in Paris in the presence of Senator Olivier Cadic, representative of French people abroad.

“We could only be seduced by xRapid dynamism and their very innovative product: an automated diagnostic tool which avoids uncertainties that exist in traditional methods and doesn’t require any experience”, said Marc Thellier.

And thanks to this obvious interest, “a public-private partnership is now running, in spite of the administrative burden” added Jean Viry-Babel.

Jean viry-Babel and Marc Thellier

Partnership agreement content

Even though the partnership was formalised last week, xRapid has been working with the CNRP at the Pitié-Salpêtrière Hospital in Paris for more than a year. They helped us test and approve xRapid-Malaria and xRapid-Lab and implement our slide staining protocol.

The main novelty of this private-public partnership is that xRapid is now supporting the PhD student, Ilhame Tantaoui. She is conducting a comparative study between xRapid diagnostic apps and the traditional microscopic analysis. Now that the agreement is concretised, xRapid and the CNRP are looking forward to joining their forces to eradicate malaria through accurate and efficient diagnosis.

xRapid’s new distributor in Kenya

xRapid is thrilled to introduce its new distributor: Prescription Products Ltd. After Benin, South Africa, Thailand, The Philippines, Indonesia, and Cambodia, we are proud to expand our distribution network to Eastern Africa. Based in Kenya, Prescription Products distributes pharmaceuticals, medical equipment and devices all over the country. The company works as well in close collaboration with the Kenya Medical Laboratory Technicians and Technologists Board to register medical devices. Thanks to our distributor’s expertise, xRapid-Malaria is now certified by the Ministry of Health and ready to sell in Kenya!

For more local information, please contact:

xRapid distributors in 2017


Focus on VSO Malawi: their humanitarian projects

Our partnership with VSO Malawi (Voluntary Service Overseas) is becoming more concrete as they are carrying on a comparative study using the xRapid-Malaria app. The purpose of this study is to assess the accuracy of the xRapid-Malaria diagnostic test in comparison to the traditional microscopy diagnostic. Three main parties are working alongside on this project: VSO Malawi, xRapid and medical institutions such as CHAM (Christian Health Association of Malawi) and the College of Medicine. By now, 23 lab technicians have been recruited by VSO Malawi to enable the accomplishment of the study and ultimately to fight malaria. We will communicate on the results by the end of April.

As a major charity, VSO Malawi is currently leading other projects in three main fields: Education, Health and Secure Livelihoods. For each field, the NGO is investing a lot of efforts to make Malawi a better place to live in.

VSO’s Education program is made of many projects but one main goal remains: making sure children can read and enumerate. 68 teachers have been taught how to use digital education technology (using iPads app). It resulted in improving learners’ global skills, increasing enrollment, assessing them in a better way and enhancing individual help. They also trained key players at the district level on budget management to help them register a visible impact on the education they provide.

VSO’s Health program comprises different projects which all aim to improve Malawians’ health practices, especially women’s and prisoners’. Aside from the comparative study with xRapid-Malaria, VSO Malawi has a major role in local prisons. The NGO is mainly active in four prisons in the country (prisons for women, youth and mixed ones). They are working to improve the prisoners’ nutrition and provide them with HIV tests and treatments. Furthermore, they chose to anticipate the prisoners’ release by training warders to conduct psychological sessions.

VSO’s Secure Livelihoods program directed most of its effort towards making communities resilient to climate change and improving communities’ economic status. They organised focus group discussions that involved several stakeholders in the organic coffee value chain (including the Government of Malawi as well as 98 farmers and other main stakeholders). Their goal is to improve market access for the poorest.

“As Malawians cut many trees for charcoal production purposes, we are trying to improve environmental awareness in local communities”

VSO seeks to have a strong impact on environment in Malawi. “As Malawians cut many trees for charcoal production purposes, we are trying to improve environmental awareness in local communities” said Anock Kapira, Head of Program at VSO Malawi. Simultaneously, they started a tree plantation program to replace trees that had been cut down.

Even if the country is politically and socially stable, VSO Malawi is redoubling its efforts to improve significantly the standards of living for local communities in the south-east African country. At xRapid, we are very proud to contribute to their Health Program by providing them with a way to prevent and eradicate malaria, and thus, save lives. We would like to thank Anock Kapira, from VSO Malawi, for his contribution to this article.

xRapid installs its R&D Centre in the south of France

xRapid has chosen to install its R&D Centre within the business incubator of the prestigious french engineer school “École des Mines de Saint-Étienne” in Gardanne, near Marseille.

“It’s a dynamic economic environment that relies on a strong industrial base and school talents, just one hour away from London” explained Jean Viry-Babel, xRapid’s CEO.

Installing xRapid’s labs on a school campus is an excellent overall strategy for the internationally based startup. Indeed, it allows them to have access to a wide range of scientific equipment, along with fully motivated and highly qualified students.

The offices opened in October 2016 and the team now consists of two full-time researchers, one assistant and five engineer students actively working on xRapid’s applications. The R&D team is currently developing a new product. We will let you know more about this project in due time…


Superbug: an emerging and quickly spreading threat to the race against malaria

While the malaria death count in Cambodia dropped to just one case in 2016, a new threat to the race against the disease arises in south-eastern Asia: superbugs. A superbug is a drug-resistant, human-killing parasite that modern medicine struggles to combat.

In the case of malaria, the superbug that is currently spreading in south-eastern Asia is multi-drug resistant. This means that the DHA-piperaquine therapy (that combines both artemisinin and piperaquine drugs) used nowadays to treat falciparum malaria, is becoming useless. This superbug is spreading rapidly in western Cambodia, north-eastern Thailand and southern Laos and only concerns the deadliest form of malaria: Plasmodium falciparum.

How did this superbug appear? Humans have unintentionally helped the parasite to develop itself. The DHA-piperaquine therapy, when taken correctly, is very efficient against malaria. But in many cases, people only take artemisinin on its own, take incomplete courses or take substandard-quality drugs. In other cases, they don’t even make it to clinics for diagnosis and treatment. All these cases, which are very common in the world’s poorest areas, drive drug resistance. That is what happened recently in south-eastern Asia.

Scientifically speaking, the emergence of the superbug is due to a single mutant parasite lineage, that replaces parasites containing less artemisinin-resistant mutations. This lineage appears to be fitter, more transmissible and able to spread more widely.

The phenomenon had already been observed twice in history. The first time (from the late 1950s to the 1970s) chloroquine-resistant malaria parasites appeared in Asia and then spread into Africa leading to a resurgence of malaria and causing millions of deaths. Chloroquine had then been replaced by sulfadoxine-pyrimethamine treatment and the exact same sequence of events happened.

If this scenario repeats itself, it could lead to a global public health disaster. Specialists say superbugs are the most dangerous threat to the progress achieved so far. Efforts to control malaria in Asia must be stepped up urgently before it spreads into Africa and becomes close to untreatable.

What are the solutions to overcome the threat? The Global Fund has created the Regional Artemisinin-Resistance Initiative (RAI) to fight this superbug. “We are currently working to close gaps in supply chains, so the right drugs are in the right places at the right time” reported the RAI Head of Program. Another solution lies in the efficient gathering of surveillance data (via efficient diagnosis reporting) so that when an outbreak flairs up, an appropriate response can be deployed immediately.


Discover our latest app, xRapid-Lab, at IoT Tech Expo

IoT Tech Expo Global, the leading internet of things event, will host two days of top-level content and discussions across seven conferences, a large exhibition, live demos, a live hackathon and a start-up incubator.

Meet xRapid’s team and discover our automated diagnostic apps at the Digital Health Innovation Lab, sponsored by the Journal of mHealth, on January 23rd and 24th at Olympia, London.



xRapid-Lab: the malaria parasite counter is now live on the App Store!

Following a successful trial period in many European tropical medicine institutes, xRapid-Lab, the automated counter for malaria cultures, is now live on the App Store.

This new tool supports all researchers working on lab culture of Plasmodium falciparum, by counting parasites and red blood cells faster.

xRapid-Lab is an automated system that counts parasites and red blood cells in Plasmodium cultures, saving time and money. Using an iPhone attached to the microscope, the app captures and analyses images from thin smear blood slides. It gives, in less than 2 minutes, the parasitemia, the parasite development stages and the red blood cells count. xRapid-Lab provides as well a detailed report for each of the samples tested and is, as a result, a simple way to track synchronous or asynchronous cultures


xRapid-Lab is under constant development, particularly regarding Plasmodium species. Please feel free to contact us with specific requests or comments.